A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
Public ClinicalTrials.gov record NCT03130959. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies.
Study identification
- NCT ID
- NCT03130959
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 166 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Months to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2017 (Actual)
- Primary completion
- Mar 10, 2020 (Actual)
- Completion
- Jan 17, 2022 (Actual)
- Last update posted
- Aug 9, 2022
2017 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0057 | Los Angeles | California | 90027 | — |
| Local Institution - 0016 | Aurora | Colorado | 80045 | — |
| Local Institution - 0046 | Gainesville | Florida | 32611 | — |
| Local Institution - 0011 | Chicago | Illinois | 60611-2605 | — |
| Local Institution - 0005 | Baltimore | Maryland | 21287 | — |
| Local Institution - 0043 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0044 | St Louis | Missouri | 63110 | — |
| Local Institution - 0004 | New York | New York | 10021 | — |
| Local Institution - 0017 | New York | New York | 10032 | — |
| Cincinnati Children'S Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Local Institution - 0066 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution | Charleston | South Carolina | 29425 | — |
| Local Institution - 0012 | Memphis | Tennessee | 38105 | — |
| Local Institution - 0042 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03130959, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03130959 live on ClinicalTrials.gov.